Literature DB >> 34410570

Association of antioxidant deficiency and the level of products of protein and lipid peroxidation in patients with the first episode of schizophrenia.

Anna Sergeevna Piatoikina1, Anastasia Alexandrovna Lyakhova2, Ilya Vladimirovich Semennov2, Tatyana Vladimirovna Zhilyaeva2, Olga Vladimirovna Kostina2, Ekaterina Sergeevna Zhukova3, Tatyana Grigorievna Shcherbatyuk3,4, Evgeny Dmitrievich Kasyanov5, Anna Sergeevna Blagonravova2, Galina Elevna Mazo5.   

Abstract

Schizophrenia is considered a multifactorial disease, where one of the pathogenetic links is oxidative stress; however, the results of studies are often contradictory, largely due to significant heterogeneity among study methods. The present study was undertaken to compare the levels of oxidative stress markers in the peripheral blood of patients with a first episode of schizophrenia (FES) and in healthy volunteers (HV). The study included 50 patients with FES and 37 HV. Blood samples were collected for spectrophotometric assessment of reduced glutathione (GSH), superoxide dismutase (SOD), catalase (CAT), malondialdehyde (MDA), aldehyde-2,4-dinitrophenylhydrazone (ADNPH), and ketone-2,4-dinitrophenylhydrazone (KDNPH) in blood plasma. Results showed that in patients with FES compared with HV, a significant decrease in CAT activity and an increase in oxidative modification of proteins (OMP) were found. In both groups, a significant increase in the level of MDA with age was revealed. In patients, the GSH plasma level was inversely proportional to the ADNPH level, and SOD activity was directly proportional to the KDNPH level. In volunteers there was no such correlation; however, there was a direct correlation between CAT activity and the levels of OMP and MDA. In both groups, a moderate direct correlation between peroxidation products was observed. The results confirm that a redox imbalance (a deficiency of antioxidants, in particular CAT, and excess OMP) may be a pathogenetic link in schizophrenia, which is manifested already at an early stage of the disease.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Catalase; Glutathione; Malondialdehyde; Oxidative modification of proteins; Oxidative stress; Schizophrenia; Superoxide dismutase

Mesh:

Substances:

Year:  2021        PMID: 34410570     DOI: 10.1007/s12031-021-01884-w

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  19 in total

1.  Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo.

Authors:  K Q Do; A H Trabesinger; M Kirsten-Krüger; C J Lauer; U Dydak; D Hell; F Holsboer; P Boesiger; M Cuénod
Journal:  Eur J Neurosci       Date:  2000-10       Impact factor: 3.386

Review 2.  Redox Signaling, Neuroinflammation, and Neurodegeneration.

Authors:  Gabriela Aguilera; Ana Laura Colín-González; Edgar Rangel-López; Anahí Chavarría; Abel Santamaría
Journal:  Antioxid Redox Signal       Date:  2017-06-06       Impact factor: 8.401

3.  Age-related changes of superoxide dismutase activity in patients with schizophrenia.

Authors:  Vladimir V Đorđević; Dušan Lazarević; Vladan Ćosić; Marinela Knežević; Vidosava B Đorđević
Journal:  Vojnosanit Pregl       Date:  2017-01       Impact factor: 0.168

4.  Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: a study of patients treated with haloperidol or clozapine.

Authors:  Clarissa Severino Gama; Mirian Salvador; Ana Cristina Andreazza; Flavio Kapczinski; Paulo Silva Belmonte-de-Abreu
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2006-01-19       Impact factor: 5.067

5.  Meta-analysis of oxidative stress in schizophrenia.

Authors:  Joshua Flatow; Peter Buckley; Brian J Miller
Journal:  Biol Psychiatry       Date:  2013-05-15       Impact factor: 13.382

6.  The oxidative stress may be induced by the elevated homocysteine in schizophrenic patients.

Authors:  Anna Dietrich-Muszalska; Joanna Malinowska; Beata Olas; Rafal Głowacki; Edward Bald; Barbara Wachowicz; Jolanta Rabe-Jabłońska
Journal:  Neurochem Res       Date:  2012-01-24       Impact factor: 3.996

7.  N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis.

Authors:  Philippe Conus; Larry J Seidman; Margot Fournier; Lijing Xin; Martine Cleusix; Philipp S Baumann; Carina Ferrari; Ann Cousins; Luis Alameda; Mehdi Gholam-Rezaee; Philippe Golay; Raoul Jenni; T-U Wilson Woo; Matcheri S Keshavan; Chin B Eap; Joanne Wojcik; Michel Cuenod; Thierry Buclin; Rolf Gruetter; Kim Q Do
Journal:  Schizophr Bull       Date:  2018-02-15       Impact factor: 9.306

8.  Obesity, altered oxidative stress, and clinical correlates in chronic schizophrenia patients.

Authors:  Huimei An; Xiangdong Du; Xingbing Huang; Lingyan Qi; Qiufang Jia; Guangzhong Yin; Chunling Xiao; Xu-Feng Huang; Yuping Ning; Ryan M Cassidy; Li Wang; Jair C Soares; Xiang Yang Zhang
Journal:  Transl Psychiatry       Date:  2018-11-29       Impact factor: 6.222

Review 9.  Oxidative Stress in Neurodegenerative Diseases: From a Mitochondrial Point of View.

Authors:  Giovanna Cenini; Ana Lloret; Roberta Cascella
Journal:  Oxid Med Cell Longev       Date:  2019-05-09       Impact factor: 6.543

10.  Oxidative stress in schizophrenia: a case-control study on the effects on social cognition and neurocognition.

Authors:  Cristina Gonzalez-Liencres; Cumhur Tas; Elliot C Brown; Soner Erdin; Ece Onur; Zeynep Cubukcoglu; Omer Aydemir; Aysen Esen-Danaci; Martin Brüne
Journal:  BMC Psychiatry       Date:  2014-09-24       Impact factor: 3.630

View more
  1 in total

1.  Prevalence of Heavy Menstrual Bleeding and Its Associated Cognitive Risks and Predictive Factors in Women With Severe Mental Disorders.

Authors:  Jianmin Shan; Hongjun Tian; Chunhua Zhou; Haibo Wang; Xiaoyan Ma; Ranli Li; Haiping Yu; Guangdong Chen; Jingjing Zhu; Ziyao Cai; Chongguang Lin; Langlang Cheng; Yong Xu; Sha Liu; Congpei Zhang; Qinghua Luo; Yunshu Zhang; Shili Jin; Chuanxin Liu; Qiuyu Zhang; Luxian Lv; Lei Yang; Jiayue Chen; Qianchen Li; Wei Liu; Weihua Yue; Xueqin Song; Chuanjun Zhuo
Journal:  Front Pharmacol       Date:  2022-07-13       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.